# A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender

> **NCT01687309** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 19 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** GSK2586184 800mg single and repeat dose
- **DRUG:** Placebo-to-match GSK2586184
- **OTHER:** GSK2586184 single dose taken with food
- **OTHER:** GSK2586184 single dose taken without food

## Key facts

- **NCT ID:** NCT01687309
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-30
- **Primary completion:** 2012-07-31
- **Final completion:** 2012-07-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01687309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01687309, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01687309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*